Leo Pharma eczema treatment recommended in two UK countries

After postponing the decision in April, the British medicines council NICE has now ruled that Adtralza can be recommended to treat atopic dermatitis.

Photo: Leo Pharma/PR

After months of back and forth, the National Institute for Health and Care Excellence (NICE) has decided that Leo Pharma’s monoclonal antibody Adtralza (tralokinumab) can be recommended as a treatment for moderate to severe eczema.

In a press release, Leo Pharma reveals that this decision means Adtralza can become a standard treatment for adult patients in England and Wales who are good candidates for systemic therapies. However, patients must have tried one systemic immuno-suppressive treatment before being prescribed Adtralza.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Further reading

Related articles

Latest news

See all jobs